- Home
- LNKS vs CUE Comparison
LNKS vs CUE Comparison
Compare LNKS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKS
- CUE
- Stock Information
- Founded
- LNKS 1995
- CUE 2014
- Country
- LNKS Malaysia
- CUE United States
- Employees
- LNKS N/A
- CUE N/A
- Industry
- LNKS
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- LNKS
- CUE Health Care
- Exchange
- LNKS NYSE
- CUE Nasdaq
- Market Cap
- LNKS 105.7M
- CUE 94.4M
- IPO Year
- LNKS 2024
- CUE 2018
- Fundamental
- Price
- LNKS $0.81
- CUE $1.32
- Analyst Decision
- LNKS
- CUE Strong Buy
- Analyst Count
- LNKS 0
- CUE 5
- Target Price
- LNKS N/A
- CUE $5.00
- AVG Volume (30 Days)
- LNKS 112.1K
- CUE 191.3K
- Earning Date
- LNKS 01-01-0001
- CUE 03-10-2025
- Dividend Yield
- LNKS N/A
- CUE N/A
- EPS Growth
- LNKS N/A
- CUE N/A
- EPS
- LNKS N/A
- CUE N/A
- Revenue
- LNKS $4,754,489.00
- CUE $9,532,000.00
- Revenue This Year
- LNKS N/A
- CUE $73.11
- Revenue Next Year
- LNKS N/A
- CUE $11.02
- P/E Ratio
- LNKS N/A
- CUE N/A
- Revenue Growth
- LNKS N/A
- CUE 149.53
- 52 Week Low
- LNKS N/A
- CUE $0.45
- 52 Week High
- LNKS N/A
- CUE $2.37
- Technical
- Relative Strength Index (RSI)
- LNKS N/A
- CUE 48.32
- Support Level
- LNKS N/A
- CUE $1.22
- Resistance Level
- LNKS N/A
- CUE $1.54
- Average True Range (ATR)
- LNKS 0.00
- CUE 0.11
- MACD
- LNKS 0.00
- CUE -0.01
- Stochastic Oscillator
- LNKS 0.00
- CUE 35.29
About LNKS LINKERS INDUSTRIES LIMITED
Linkers Industries Ltd is a company which acts as a manufacturer and a supplier of wire, cable harnesses with their manufacturing operations in Malaysia. Wire/cable harness refers to an assembly of wires/cables bound together with straps, cable ties and electrical tapes to transmit signals or electrical power. Company works closely with customers in each stage of a product's life cycle, including design, prototyping and production. Geographically company provides services in Thailand, Malaysia, Switzerland, United States of America, and many others, maximum revenue gained from Thailand.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.